Myriad Genetics Inc., a Salt Lake City-based provider of molecular diagnostics testing, has named Sam Raha, the company’s current chief operating officer, as president and CEO of the company and as a member of the board. The change will be effective April 30. Raha replaces Paul J. Diaz, who is stepping down to join private equity firm Cressey & Co. Diaz will continue to serve as a consultant to Raha and the board for another year.
“Since joining Myriad in December 2023, Sam has played an integral role in shaping the company’s long-term growth strategy, while delivering new perspectives and expertise to advance our Please log in to see the rest of this story.
